3643companies in the directory 1104ISIN verified against the check digit 7exchanges 14sectors No real-time quotes — a reference work, not a trading platform3643companies in the directory 1104ISIN verified against the check digit 7exchanges 14sectors No real-time quotes — a reference work, not a trading platform
DE · EN Newsletter
Biotech & Pharma Symbolbild · KI-generiert
Biotech & Pharma NVCR

NovoCure Limited

NVCR NASDAQ JE00BYSS4X48 Biotech & Pharma

Stock factsheet

TickerNVCR
ExchangeNASDAQ
ISINJE00BYSS4X48
WKN
SectorBiotech & Pharma
Size class Small Cap
Market capitalisation 1,73 Mrd. USD As of 2026-08-03

Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.

Company profile

NovoCure develops and markets an electrical cancer therapy known as Tumor Treating Fields (TTFields), which inhibits tumour cell growth through alternating electric fields. Its primary product, Optune, is approved for the treatment of glioblastoma, among other indications.

Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.

Share price

Price data from TradingView, possibly delayed. Not investment advice.

Comparable companies

Companies in the Biotech & Pharma sector of a similar size.

CompanyTickerExchangeMarket cap
NovoCure LimitedNVCR NASDAQ1,73 Mrd. USD
Alamar Biosciences, Inc. ALMRNASDAQ 1,76 Mrd. USD
Maravai LifeSciences Holdings, Inc. MRVINASDAQ 1,70 Mrd. USD
Sienna Senior Living Inc. SIATSX 1,76 Mrd. USD
Syndax Pharmaceuticals, Inc. SNDXNASDAQ 1,69 Mrd. USD
Taysha Gene Therapies, Inc. TSHANASDAQ 1,68 Mrd. USD
AbCellera Biologics Inc. ABCLNASDAQ 1,68 Mrd. USD

Investor Relations

Annual reports Not recorded yet
Investor presentation Not recorded yet
Analyst coverage Not recorded yet

We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.

Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.